{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:34:40Z","timestamp":1793316880500,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020594","name":"GenSight Biologics SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","surveyophthalmol.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.survophthal.2024.10.002","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T04:06:55Z","timestamp":1729051615000},"page":"283-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Meta-analysis of treatment outcomes for patients with m.11778G&gt;A MT-ND4 Leber hereditary optic neuropathy"],"prefix":"10.1016","volume":"70","author":[{"given":"Nancy J.","family":"Newman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Biousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Yu-Wai-Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Carelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vignal-Clermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Montestruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Taiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Alain","family":"Sahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2024.10.002_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajo.2022.12.014","article-title":"Childhood-onset leber hereditary optic neuropathy-clinical and prognostic insights","volume":"249","author":"Barboni","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.10.002_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/WNO.0000000000001367","article-title":"Long-term follow-up after unilateral intravitreal gene therapy for leber hereditary optic neuropathy: the RESTORE study","volume":"41","author":"Biousse","year":"2021","journal-title":"J Neuro-Ophthalmol J North Am Neuro-Ophthalmol Soc"},{"key":"10.1016\/j.survophthal.2024.10.002_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ajo.2022.11.004","article-title":"Visual outcomes and optical coherence tomography biomarkers of vision improvement in patients with leber hereditary optic neuropathy treated with idebenone","volume":"247","author":"Borrelli","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2024.10.002_bib4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/WNO.0000000000000570","article-title":"International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy","volume":"37","author":"Carelli","year":"2017","journal-title":"J Neuroophthalmol D\u00e9C"},{"issue":"Pt 9","key":"10.1016\/j.survophthal.2024.10.002_bib5","article-title":"Idebenone treatment in Leber\u2019s hereditary optic neuropathy","volume":"134","author":"Carelli","year":"2011","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.survophthal.2024.10.002_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-12-821751-1.00010-5","article-title":"Mitochondrial optic neuropathies","volume":"194","author":"Carelli","year":"2023","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.10.002_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40123-022-00611-x","article-title":"Indirect comparison of lenadogene nolparvovec gene therapy versus natural history in patients with leber hereditary optic neuropathy carrying the m.11778G>A MT-ND4 mutation","volume":"12","author":"Carelli","year":"2023","journal-title":"Ophthalmol Ther F\u00e9vr"},{"issue":"4","key":"10.1016\/j.survophthal.2024.10.002_bib8","first-page":"558","article-title":"Real-world clinical experience with idebenone in the treatment of leber hereditary optic neuropathy","volume":"40","author":"Catarino","year":"2020","journal-title":"J Neuro-Ophthalmol J North Am Neuro-Ophthalmol Soc D\u00e9C"},{"issue":"3","key":"10.1016\/j.survophthal.2024.10.002_bib9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/WNO.0000000000001564","article-title":"The impact of leber hereditary optic neuropathy on the quality of life of patients and their relatives: a qualitative study","volume":"42","author":"Chen","year":"2022","journal-title":"J Neuro-Ophthalmol J North Am Neuro-Ophthalmol Soc"},{"issue":"12","key":"10.1016\/j.survophthal.2024.10.002_bib10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s11910-022-01246-y","article-title":"Developments in the treatment of leber hereditary optic neuropathy","volume":"22","author":"Chen","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"10.1016\/j.survophthal.2024.10.002_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/13102818.2023.2255073","article-title":"Leber\u2019s hereditary optic neuropathy: clinical and genetic analysis of Bulgarian patients","volume":"37","author":"Cherninkova","year":"2023","journal-title":"Biotechnol Biotechnol Equip"},{"key":"10.1016\/j.survophthal.2024.10.002_bib12","unstructured":"Chiesi GmbH. Dossier for the benefit assessment according to \u00a7 35a SGB V. Idebenone. Module 4 A. Appendix 4-G: Supplementary documents. Treatment of visual disorders in adolescents and adults with Leber\u2019s hereditary optic neuropathy (LHON). 30 mars 2022;"},{"issue":"6","key":"10.1016\/j.survophthal.2024.10.002_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0021-5155(01)00423-3","article-title":"Leber\u2019s hereditary optic neuropathy in Thailand","volume":"45","author":"Chuenkongkaew","year":"2001","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.10.002_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"6","key":"10.1016\/j.survophthal.2024.10.002_bib15","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/aos.15153","article-title":"Clinical outcomes of treatment with idebenone in Leber\u2019s hereditary optic neuropathy in the Netherlands: a national cohort study","volume":"100","author":"van Everdingen","year":"2022","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"4","key":"10.1016\/j.survophthal.2024.10.002_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann Math Stat"},{"key":"10.1016\/j.survophthal.2024.10.002_bib17","unstructured":"Guy J., Feuer W., Davis J.L., et al. Gene Therapy for Leber Hereditary Optic Neuropathy An update of Where We Stand (Clinicaltrials.gov number: NCT02161380). Poster at the ARVO 2019 conference."},{"issue":"11","key":"10.1016\/j.survophthal.2024.10.002_bib18","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","article-title":"Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results","volume":"124","author":"Guy","year":"2017","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2024.10.002_bib19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ana.10354","article-title":"Rescue of a mitochondrial deficiency causing Leber Hereditary Optic Neuropathy","volume":"52","author":"Guy","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.survophthal.2024.10.002_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.651639","article-title":"Leber hereditary optic neuropathy: review of treatment and management","volume":"12","author":"Hage","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.10.002_bib21","first-page":"96","article-title":"Clinical features of Japanese Leber\u2019s hereditary optic neuropathy with 11778 mutation of mitochondrial DNA.","volume":"39","author":"Hotta","year":"1995","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.10.002_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10384-020-00789-2","article-title":"Characteristics of Japanese patients with Leber\u2019s hereditary optic neuropathy and idebenone trial: a prospective, interventional, non-comparative study","volume":"65","author":"Ishikawa","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.10.002_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.770069","article-title":"Observation of peripapillary choroidal vascularity in natural disease course and after gene therapy for leber\u2019s hereditary optic neuropathy","volume":"8","author":"Jiang","year":"2021","journal-title":"Front Med"},{"issue":"7","key":"10.1016\/j.survophthal.2024.10.002_bib24","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1167\/iovs.08-3166","article-title":"Quality of life in patients with leber hereditary optic neuropathy","volume":"50","author":"Kirkman","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Pt 9","key":"10.1016\/j.survophthal.2024.10.002_bib25","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/brain\/awr170","article-title":"A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy","volume":"134","author":"Klopstock","year":"2011","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.survophthal.2024.10.002_bib26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajo.2022.02.023","article-title":"Leber hereditary optic neuropathy gene therapy: adverse events and visual acuity results of all patient groups","volume":"241","author":"Lam","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2024.10.002_bib27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jamaophthalmol.2013.7971","article-title":"Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy: preparation for gene therapy clinical trial","volume":"132","author":"Lam","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2024.10.002_bib28","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1136\/bjophthalmol-2016-310072","article-title":"Childhood-onset Leber hereditary optic neuropathy","volume":"101","author":"Majander","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.10.002_bib29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12886-017-0583-3","article-title":"Visual prognosis better in eyes with less severe reduction of visual acuity one year after onset of Leber hereditary optic neuropathy caused by the 11,778 mutation","volume":"17","author":"Mashima","year":"2017","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.10.002_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00041327-200020030-00006","article-title":"Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy?","volume":"20","author":"Mashima","year":"2000","journal-title":"J Neuro-Ophthalmol J North Am Neuro-Ophthalmol Soc"},{"issue":"1","key":"10.1016\/j.survophthal.2024.10.002_bib31","first-page":"15","article-title":"Clinical and optic disc characteristics of patients showing visual recovery in leber hereditary optic neuropathy","volume":"40","author":"Moon","year":"2020","journal-title":"J Neuro-Ophthalmol J North Am Neuro-Ophthalmol Soc mars"},{"issue":"3","key":"10.1016\/j.survophthal.2024.10.002_bib32","first-page":"488","article-title":"Homoplasmic and exclusive ND4 gene mutation in Japanese pedigrees with Leber\u2019s disease.","volume":"34","author":"Nakamura","year":"1993","journal-title":"Invest Ophthalmol Vis Sci mars"},{"issue":"4","key":"10.1016\/j.survophthal.2024.10.002_bib33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/WNO.0000000000001045","article-title":"Visual outcomes in Leber hereditary optic neuropathy patients with the m.11778G>A (MTND4) mitochondrial DNA mutation","volume":"40","author":"Newman","year":"2020","journal-title":"J Neuro-Ophthalmol J North Am Neuro-Ophthalmol Soc"},{"issue":"6","key":"10.1016\/j.survophthal.2024.10.002_bib34","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0002-9394(14)76784-4","article-title":"The clinical characteristics of pedigrees of Leber\u2019s hereditary optic neuropathy with the 11778 mutation","volume":"111","author":"Newman","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.10.002_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.662838","article-title":"Intravitreal gene therapy vs. natural history in patients with leber hereditary optic neuropathy carrying the m.11778G>A ND4 mutation: systematic review and indirect comparison","volume":"12","author":"Newman","year":"2021","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.survophthal.2024.10.002_bib36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","article-title":"Efficacy and safety of intravitreal gene therapy for leber hereditary optic neuropathy treated within 6 months of disease onset","volume":"128","author":"Newman","year":"2021","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2024.10.002_bib37","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/brain\/awac421","article-title":"Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy","volume":"146","author":"Newman","year":"2023","journal-title":"Brain J Neurol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.10.002_bib38","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0161-6420(96)30665-9","article-title":"Ophthalmologic findings in Leber hereditary optic neuropathy, with special reference to mtDNA mutations","volume":"103","author":"Nikoskelainen","year":"1996","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2024.10.002_bib39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/jmg.31.4.280","article-title":"Leber\u2019s hereditary optic neuropathy: correlations between mitochondrial genotype and visual outcome","volume":"31","author":"Oostra","year":"1994","journal-title":"J Med Genet"},{"issue":"12","key":"10.1016\/j.survophthal.2024.10.002_bib40","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s00417-019-04444-6","article-title":"Visual function in chronic Leber\u2019s hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset","volume":"257","author":"Pemp","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol D\u00e9C"},{"issue":"1\u20132","key":"10.1016\/j.survophthal.2024.10.002_bib41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.mito.2006.11.015","article-title":"Cosegregation of the ND4 G11696A mutation with the LHON-associated ND4 G11778A mutation in a four generation Chinese family","volume":"7","author":"Qu","year":"2007","journal-title":"Mitochondrion"},{"issue":"3","key":"10.1016\/j.survophthal.2024.10.002_bib42","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2008.10.022","article-title":"Extremely low penetrance of Leber\u2019s hereditary optic neuropathy in 8 Han Chinese families carrying the ND4 G11778A mutation","volume":"116","author":"Qu","year":"2009","journal-title":"Ophthalmology"},{"issue":"Pt 2","key":"10.1016\/j.survophthal.2024.10.002_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/brain\/118.2.319","article-title":"The clinical features of Leber\u2019s hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation","volume":"118","author":"Riordan-Eva","year":"1995","journal-title":"Brain J Neurol avr"},{"key":"10.1016\/j.survophthal.2024.10.002_bib44","unstructured":"Romagnoli M., Amore G., D\u2019Agati P., et al. Therapeutic intervention in Leber Hereditary Optic Neuropathy: later is better? Personal communication;"},{"key":"10.1016\/j.survophthal.2024.10.002_bib45","first-page":"334","article-title":"Pan-American mDNA haplogroups in Chilean patients with Leber\u2019s hereditary optic neuropathy.","volume":"20","author":"Romero","year":"2014","journal-title":"Mol Vis"},{"issue":"2","key":"10.1016\/j.survophthal.2024.10.002_bib46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ajo.2003.08.010","article-title":"Ophthalmologic findings in a large pedigree of 11778\/Haplogroup J Leber hereditary optic neuropathy","volume":"137","author":"Sadun","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2024.10.002_bib47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/08820538.2024.2323114","article-title":"Clinical Characteristics of m.11778G>a leber hereditary optic neuropathy with favorable outcomes","volume":"39","author":"Samuel Kim","year":"2024","journal-title":"Semin Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.10.002_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/01658107.2022.2032761","article-title":"The natural history of leber\u2019s hereditary optic neuropathy in an irish population and assessment for prognostic biomarkers","volume":"46","author":"Stephenson","year":"2022","journal-title":"Neuro-Ophthalmol Aeolus Press"},{"issue":"1","key":"10.1016\/j.survophthal.2024.10.002_bib50","first-page":"10","article-title":"Visual recovery in patients with Leber\u2019s hereditary optic neuropathy and the 11778 mutation.","volume":"12","author":"Stone","year":"1992","journal-title":"J Clin Neuroophthalmol mars"},{"issue":"2","key":"10.1016\/j.survophthal.2024.10.002_bib51","first-page":"201","article-title":"Safety of intravitreal gene therapy for treatment of subjects with leber hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: the REVEAL study","volume":"35","author":"Vignal-Clermont","year":"2021","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther mars"},{"issue":"1","key":"10.1016\/j.survophthal.2024.10.002_bib52","article-title":"Efficacy and safety of rAAV2-ND4 treatment for Leber\u2019s hereditary optic neuropathy","volume":"6","author":"Wan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.survophthal.2024.10.002_bib53","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","article-title":"Long-term outcomes of gene therapy for the treatment of Leber\u2019s hereditary optic neuropathy","volume":"10","author":"Yang","year":"2016","journal-title":"EBioMedicine"},{"issue":"40","key":"10.1016\/j.survophthal.2024.10.002_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005110","article-title":"Evaluation of Leber\u2019s hereditary optic neuropathy patients prior to a gene therapy clinical trial","volume":"95","author":"Yang","year":"2016","journal-title":"Med (Baltim)"},{"issue":"6","key":"10.1016\/j.survophthal.2024.10.002_bib55","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2174\/1566523218666181105125245","article-title":"Clinical observation of patients with leber\u2019s hereditary optic neuropathy before gene therapy","volume":"18","author":"Yuan","year":"2018","journal-title":"Curr Gene Ther"},{"issue":"3","key":"10.1016\/j.survophthal.2024.10.002_bib56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000487485","article-title":"Visual field variability after gene therapy for Leber\u2019s hereditary optic neuropathy","volume":"60","author":"Yuan","year":"2018","journal-title":"Ophthalmic Res"},{"issue":"3","key":"10.1016\/j.survophthal.2024.10.002_bib57","article-title":"Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: the LEROS nonrandomized controlled trial","volume":"5","author":"Yu-Wai-Man","year":"2024","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.survophthal.2024.10.002_bib58","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.preteyeres.2010.11.002","article-title":"Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies","volume":"30","author":"Yu-Wai-Man","year":"2011","journal-title":"Prog Retin Eye Res"},{"issue":"573","key":"10.1016\/j.survophthal.2024.10.002_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz7423","article-title":"Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy","volume":"12","author":"Yu-Wai-Man","year":"2020","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.survophthal.2024.10.002_bib60","first-page":"818","article-title":"Natural history of patients with Leber hereditary optic neuropathy-results from the REALITY study","volume":"36","author":"Yu-Wai-Man","year":"2022","journal-title":"Eye Lond Engl"},{"issue":"6","key":"10.1016\/j.survophthal.2024.10.002_bib61","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00401-016-1625-2","article-title":"A neurodegenerative perspective on mitochondrial optic neuropathies","volume":"132","author":"Yu-Wai-Man","year":"2016","journal-title":"Acta Neuropathol (Berl)"},{"issue":"4","key":"10.1016\/j.survophthal.2024.10.002_bib62","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ymgme.2010.04.013","article-title":"Very high penetrance and occurrence of Leber\u2019s hereditary optic neuropathy in a large Han Chinese pedigree carrying the ND4 G11778A mutation","volume":"100","author":"Zhou","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.survophthal.2024.10.002_bib63","unstructured":"Raxone | European Medicines Agency [Internet]. [cit\u00e9 9 f\u00e9vr. 2024]. Disponible sur: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/raxone."}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625724001309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625724001309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T09:10:43Z","timestamp":1736759443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625724001309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0039625724001309"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2024.10.002","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis of treatment outcomes for patients with m.11778G>A MT-ND4 Leber hereditary optic neuropathy","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2024.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}